TrialJCO precision oncology2026

Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer.

Robert L Coleman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.